Summary of clinical outcomes of historical non-caplacizumab cohort vs caplacizumab cohort
| . | Non-caplacizumab cohort (n = 16), median (range) . | Caplacizumab cohort (n = 17), median (range) . | P value . |
|---|---|---|---|
| Days to platelet count normalization | 6 (3-29) | 4 (2-10) | .2 |
| Days to ADAMTS13 activity ≥10% IU/dL∗ | 10.5 (2-929) | 5 (1-72) | .3 |
| Days to ADAMTS13 activity ≥20% IU/dL∗ | 14 (2-929) | 5 (1-72) | .1 |
| Days to ADAMTS13 activity ≥30% IU/dL∗ | 18 (3-929) | 9 (1-230) | .1 |
| Platelet count at time of caplacizumab discontinuation, × 109/L | — | 191 (92-467) | — |
| Platelet count at time of PLEX discontinuation, × 109/L | 249 (166-466) | 247 (107-375) | .7 |
| ADAMTS13 activity at time of caplacizumab discontinuation, IU/dL | — | 50 (1-97) | — |
| ADAMTS13 activity at time of PLEX discontinuation, IU/dL | 55 (1-70) | 58 (1-97) | .6 |
| Length of stay, d | 13 (6-30) | 15 (5-25) | .8 |
| ADAMTS13 activity 30 d after PLEX, IU/dL | 84 (50-103; n = 12) | 70 (1-95; n = 15) | .02 |
| Patients with iTTP exacerbation, n (%) | 1 (6) | 0 | .3 |
| Patients with iTTP relapse, n (%) | 3 (18.8) | 5 (29) | .3 |
| Days after PLEX to iTTP relapse | 175 (151-203) | 234 (102-1053) | .79 |
| Days after caplacizumab to iTTP relapse | — | 237 (102-1053) | — |
| Caplacizumab-associated bleeding complications, n (%) | — | 1 (6) | — |
| Mortality, n (%) | 0 | 0 | — |
| . | Non-caplacizumab cohort (n = 16), median (range) . | Caplacizumab cohort (n = 17), median (range) . | P value . |
|---|---|---|---|
| Days to platelet count normalization | 6 (3-29) | 4 (2-10) | .2 |
| Days to ADAMTS13 activity ≥10% IU/dL∗ | 10.5 (2-929) | 5 (1-72) | .3 |
| Days to ADAMTS13 activity ≥20% IU/dL∗ | 14 (2-929) | 5 (1-72) | .1 |
| Days to ADAMTS13 activity ≥30% IU/dL∗ | 18 (3-929) | 9 (1-230) | .1 |
| Platelet count at time of caplacizumab discontinuation, × 109/L | — | 191 (92-467) | — |
| Platelet count at time of PLEX discontinuation, × 109/L | 249 (166-466) | 247 (107-375) | .7 |
| ADAMTS13 activity at time of caplacizumab discontinuation, IU/dL | — | 50 (1-97) | — |
| ADAMTS13 activity at time of PLEX discontinuation, IU/dL | 55 (1-70) | 58 (1-97) | .6 |
| Length of stay, d | 13 (6-30) | 15 (5-25) | .8 |
| ADAMTS13 activity 30 d after PLEX, IU/dL | 84 (50-103; n = 12) | 70 (1-95; n = 15) | .02 |
| Patients with iTTP exacerbation, n (%) | 1 (6) | 0 | .3 |
| Patients with iTTP relapse, n (%) | 3 (18.8) | 5 (29) | .3 |
| Days after PLEX to iTTP relapse | 175 (151-203) | 234 (102-1053) | .79 |
| Days after caplacizumab to iTTP relapse | — | 237 (102-1053) | — |
| Caplacizumab-associated bleeding complications, n (%) | — | 1 (6) | — |
| Mortality, n (%) | 0 | 0 | — |
During an acute presentation of iTTP.